Dr. Leigh MacConell is a global drug development professional with a robust history of success in the design and execution of clinical drug programs for major regulatory milestones across multiple therapeutic areas, including metabolic and liver diseases. Before joining HighTide, Dr. MacConell served as Senior Vice President, Clinical Development at Intercept Pharmaceuticals, where she provided strategic and scientific leadership to their global clinical development programs across the portfolio and all therapeutic areas culminating in a first-in-class approval for primary biliary cholangitis and precedent-setting clinical development plans in MASH. Prior to Intercept, she served in various management positions at Amylin Pharmaceuticals, where she ultimately served as clinical lead of their GLP-1 Receptor Agonist portfolio, helping to secure multiple approvals of Byetta® and Bydureon® for the treatment of T2DM, globally.
Dr. MacConell has a Ph.D. in neuroendocrinology from the University of California, San Diego and completed her post-doctoral training at the Salk Institute.